-
2023-510075-63-00
5
Patients with ventilator-associated tracheobronchitis
-
2024-513889-19-00
5
Multiple Myeloma
-
2024-516215-24-00
4
TAkayasu ARteritiS
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2024-511855-16-00
5
2019-07-25
Onco-hematology
-
2023-505046-26-00
5
2026-05-07
Colon carcinoma
-
2023-508930-33-00
4
2026-01-30
Non-infectious active cryoglobulinemia vasculitis who are either refra
-
2024-515349-41-00
4
2025-07-29
Metastatic Breast Cancer HR+, HER2-
-
2024-515787-31-00
5
2025-07-18
Patient with early triple-negative breast cancer (TNBC) achieving path
-
2024-516418-39-00
5
2025-07-09
Multiple Myeloma
-
2023-507873-16-00
11
2025-03-04
1st line treatment for unresectable metastatic colorectal cancer
-
2023-504079-26-01
5
2025-02-10
Arthroplastie totale de hanche
-
2024-510981-18-00
5
2024-12-12
Multiple Myeloma
Multiple myeloma (MM) is a B cell malignancy and is o
-
2024-515297-27-00
5
2024-08-14
colon carcinoma
-
2023-507407-59-00
5
2024-07-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2024-513371-41-00
4
2024-04-25
Severe uveitis of Behçet’s disease
-
2023-504366-36-00
5
2024-02-17
de novo acute respiratory failure
-
2023-508827-10-00
4
2025-10-13
Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
-
2024-512890-28-00
5
2023-03-20
Primary immune thrombocytopenia (ITP)
-
2024-514480-26-00
4
2022-10-12
Post-menopausal women with localized luminal A breast cancer and consi
-
2024-514088-25-00
5
2019-10-07
Multiple Myeloma
-
2024-513206-65-00
5
2018-08-10
resected squamous cell carcinoma of head and neck
-
2024-517489-41-00
5
2017-03-27
High-risk stage III colon cancer
-
2024-510704-37-00
5
2017-03-22
ER+/HER2- metastatic breast cancer